| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
12,960,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.000001 - $1.25 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile 9 Meters Biopharma is a clinical-stage company. Co.'s product development pipeline include: Vurolenatide, which is a long-acting glucagon-like peptide-1 receptor agonist that combines exenatide with a proprietary extended half-life technology for treatment of short bowel syndrome; Larazotide, which is being developed for the treatment of celiac disease; NM-102, which is a small molecule peptide that is being developed as a potential microbiome modulator and is undergoing an indication selection process; and NM-003, which is a proprietary long-acting glucagon-like peptide-2 agonist with improved serum half-life compared with short-acting versions.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
472,383 |
| Total Buy Value |
$0 |
$0 |
$0 |
$151,319 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
5 |
| Total Shares Sold |
0 |
0 |
0 |
9,100 |
| Total Sell Value |
$0 |
$0 |
$0 |
$11,011 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sitar Edward J |
Chief Financial Officer |
• – – |
2021-09-14 |
4 |
B |
$1.22 |
$18,300 |
D/D |
15,000 |
194,338 |
2.74 |
-38% |
|
| Sirgo Mark A |
Director |
– • – |
2021-09-07 |
4 |
B |
$1.36 |
$99,999 |
D/D |
73,529 |
1,172,595 |
2.39 |
-36% |
|
| Constantino Michael T. |
Director |
– • – |
2021-08-24 |
4 |
B |
$1.14 |
$20,520 |
D/D |
18,000 |
52,108 |
2.39 |
-22% |
|
| Sirgo Mark A |
Director |
– • – |
2021-08-20 |
4 |
B |
$1.10 |
$27,500 |
D/D |
25,000 |
1,099,066 |
2.39 |
-11% |
|
| Temperato John |
Chief Executive Officer |
• • – |
2021-08-18 |
4 |
B |
$1.05 |
$26,250 |
D/D |
25,000 |
1,102,522 |
2.81 |
-10% |
|
| Orbimed Israel Biofund Gp Limited Partnership |
10% Owner |
– – • |
2021-06-25 |
4 |
S |
$1.21 |
$19,347,750 |
I/I |
(15,989,876) |
8,565,974 |
|
-6% |
|
| Orbimed Israel Biofund Gp Limited Partnership |
10% Owner |
– – • |
2021-06-24 |
4 |
S |
$1.38 |
$440,572 |
I/I |
(319,255) |
24,555,850 |
|
5% |
|
| Orbimed Israel Biofund Gp Limited Partnership |
10% Owner |
– – • |
2021-06-23 |
4 |
S |
$1.36 |
$1,144,644 |
I/I |
(841,650) |
24,875,105 |
|
6% |
|
| Orbimed Israel Biofund Gp Limited Partnership |
10% Owner |
– – • |
2021-05-11 |
4 |
OE |
$0.62 |
$20,836 |
I/I |
31,944 |
25,748,699 |
|
- |
|
| Sirgo Mark A |
Director |
– • – |
2020-12-15 |
4 |
B |
$0.65 |
$150,000 |
D/D |
230,769 |
774,066 |
2.39 |
66% |
|
| Temperato John |
Chief Executive Officer |
• • – |
2020-12-15 |
4 |
B |
$0.65 |
$100,000 |
D/D |
153,846 |
977,522 |
2.81 |
66% |
|
| Sitar Edward J |
Chief Financial Officer |
• – – |
2020-12-15 |
4 |
B |
$0.65 |
$40,000 |
D/D |
61,538 |
129,338 |
2.74 |
66% |
|
| Temperato John |
Chief Executive Officer |
• • – |
2020-11-27 |
4 |
A |
$0.00 |
$0 |
D/D |
203,667 |
823,676 |
|
- |
|
| Sirgo Mark A |
Director |
– • – |
2020-10-30 |
4 |
A |
$0.00 |
$0 |
D/D |
4,513 |
543,297 |
|
- |
|
| Darvish Nissim |
Director |
– • • |
2020-10-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,943,734 |
25,716,755 |
|
- |
|
| Temperato John |
Chief Executive Officer |
• • – |
2020-10-30 |
4 |
A |
$0.00 |
$0 |
D/D |
4,513 |
620,009 |
|
- |
|
| Orbimed Israel Biofund Gp Limited Partnership |
Director |
– • • |
2020-10-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,943,734 |
25,716,755 |
|
- |
|
| Sirgo Mark A |
Director |
– • – |
2020-09-11 |
4 |
B |
$0.65 |
$14,004 |
I/I |
21,485 |
21,485 |
2.1 |
83% |
|
| Sirgo Mark A |
Director |
– • – |
2020-09-11 |
4 |
B |
$0.68 |
$52,360 |
D/D |
77,000 |
538,784 |
2.39 |
83% |
|
| Sirgo Mark A |
Director |
– • – |
2020-09-10 |
4 |
B |
$0.60 |
$30,000 |
D/D |
50,000 |
461,784 |
2.39 |
98% |
|
| Temperato John |
Chief Executive Officer |
• • – |
2020-08-21 |
4 |
B |
$0.69 |
$48,300 |
D/D |
70,000 |
615,496 |
2.81 |
62% |
|
| Constantino Michael T. |
Director |
– • – |
2020-08-20 |
4/A |
B |
$0.75 |
$20,001 |
D/D |
26,509 |
26,509 |
2.39 |
- |
|
| Constantino Michael T. |
Director |
– • – |
2020-08-20 |
4 |
B |
$0.75 |
$25,581 |
D/D |
34,108 |
34,108 |
2.39 |
18% |
|
| Sirgo Mark A |
Director |
– • – |
2020-08-17 |
4 |
B |
$0.56 |
$56,000 |
D/D |
100,000 |
411,784 |
2.39 |
60% |
|
| Temperato John |
Chief Executive Officer |
• • – |
2020-08-17 |
4 |
B |
$0.57 |
$19,831 |
D/D |
35,000 |
545,496 |
2.81 |
60% |
|
40 Records found
|
|
Page 1 of 2 |
|
|
